NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy
This article was originally published in The Pink Sheet Daily
NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.
You may also be interested in...
The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.
In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.
Its favorable recommendation of Alimta as maintenance therapy in lung cancer patients is the last before the U.K. election on May 6.